Abstract: The present invention relates to a method for suppressing aggregation of polypeptide. Specifically, the present invention relates to a method for suppressing, in a solution comprising an antibody or an Fc region-containing protein, formation of an aggregate derived from an antibody or an Fc region-containing protein having a non-native conformation, the method comprising: the steps of (i) binding an AF.2A1 polypeptide or an analog thereof with an aggregate derived from the antibody or Fc region-containing protein having a non-native conformation in the solution; and (ii) collecting the aggregate bound to the polypeptide or analog thereof from the solution.

Abstract: The present disclosure relates to a peptoid compound, and a derivative, a salt, a preparation method and use thereof. The peptoid compound includes the following subunits: 4-phenylphenethylamine, monoprotected ethylenediamine, monoprotected tetramethylenediamine, 3,4-methylenedioxybenzylamine, isobutylamine, and R(+)-?-methylbenzylamine, in which molecular formulas of the subunits are as follows: in which P is independently an amino protecting group.

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.

Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.

Abstract: In some aspects, the present invention cell-penetrating compstatin analog and compositions comprising cell-penetrating compstatin analog. In some aspects, the invention further provides methods of using cell-penetrating compstatin analogs treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ, to inhibit production or release of biologically active C3 cleavage products.

Abstract: The present invention discloses a strain of bacteria producing DHA and/or EPA, six gene fragments in the bacterial genome, and uses thereof. The strain is Schizoochytrium limacinum HS01, which has the accession number of CGMCC No. 13746 at China General Microbiological Culture Collection Center. The six gene fragments are composed of gene fragment 1 to gene fragment 6, and the nucleotide sequences are sequentially as shown in SEQ ID NO: 3 to SEQ ID NO: 8 in the Sequence Listing. The experiments prove that fermentation broth containing DHA and EPA can be obtained by fermenting Schizoochytrium limacinum HS01; the recombinant strain is obtained by introducing gene fragment 1 to gene fragment 6 into Schizoochytrium limacinum MYA-1381; the ability the recombinant strain for producing DHA and EPA is greatly improved.

Abstract: The invention relates to expressing proteins in the axons of mammalian neurons. The invention provides nucleic acids that can be used to express a selected polypeptide in neuronal axons, viruses that can be used deliver nucleic acids of the invention into neuronal axons, as well as methods for doing so. Thus, the invention provides pharmaceutical compositions comprising viruses of the invention, as well as their use in methods of treating injured axons or conditions associated with aberrant axon growth or function.

Abstract: The invention relates to novel polypeptide analogs of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogs thereof for neuroprotective and neurotrophic effects.

Abstract: The present invention provides methods for generating functional derivatives of effector polypeptides (e.g., hormones and receptor ligands) embedded in a different protein scaffold (e.g., antibody scaffolds). The methods involve modifying the effector polypeptide with a combinatorial library of terminal linker sequences, inserting the modified sequences into the host scaffold, and then selecting functional derivatives from the library of modified polypeptide sequences embedded in the host scaffold. As exemplifications, the invention also provides specific functional derivatives of leptin, scFSH and scRelaxin embedded in an antibody scaffold, as well as therapeutic applications of such functional fusion molecules.

Abstract: The invention provides for mammalian cells capable of producing recombinant CTLA4-Ig and variants thereof. The invention also provides for compositions comprising CTLA4-Ig and formulations thereof. The invention further provides for methods for mass-producing CTLA4-Ig from mammalian cells capable of producing this recombinant protein, and for purifying the CTLA4-Ig.

Abstract: Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes located on a single molecule or located on different molecules.

Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.

Abstract: Provided is a VHH antibody including an amino acid sequence in which at least one selected from the group consisting of glycine in position 36, arginine in position 50, and glycine in position 78, on the basis of IMGT numbering, of the amino acid sequence represented by SEQ ID NO: 1 is substituted with another amino acid. The VHH antibody according to the present disclosure is thermostable.

Abstract: Anti-microbial monoclonal antibodies and variant antibodies having a heavy chain constant regions with at least one amino acid substitution are provided. Such antibodies may be used to prevent or treat microbial infections.

Abstract: The invention describes a method of diagnosing an individual as having an increased likelihood of having an autism spectrum disorder and in some instances, selecting a therapy. The invention is related to a system or a kit for performing such a method.

Abstract: The present invention provides antibodies and antigen binding fragments thereof that bind to human Follistatin-Like-3 (FSTL3) protein, compositions comprising such antibodies, and methods of making and using such antibodies.

Abstract: Disclosed herein are low immunogenic human anti-TNF-?antibodies which can inhibit the apopotosis of cells induced by TNF-?. The invented low immunogenic human anti-TNF-? antibodies are capable of binding to TNF-? specifically. The invention presents the human anti-TNF-?antibodies which bind to TNF-? with similar affinities as Adalimumab. Most importantly, the invented human anti-TNF-? antibodies showed reduced immunogenicities in vivo, which made them safer candidate for antibody drug and other biotherapy. The invention also features method of de-immunogenicity of antibody drugs by identification, replacement of high immunogenic FR sequence(s) of the human antibody with low immunogenic FR sequences from other human IgGs, and significantly reduce the risk of human anti-human immunogenicity and improve the efficacy of antibody drugs.

Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.

Abstract: Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-? antibodies as well as IFN-? binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.

Abstract: The invention provides anti-CD79b antibodies and methods of using the same.

Abstract: The present invention relates to a binding molecule having a binding site within the ectodomain of the triggering receptor expressed on myeloid cells 2 (TREM2), wherein the binding molecule inhibits TREM2 cleavage. Said binding molecule is particularly useful for treating and/or preventing a neurological disorder, such as a neurodegenerative disorder. Also encompassed by the present invention is a pharmaceutical composition for use in treating and/or preventing a neurological disorder, wherein the pharmaceutical composition comprises the binding molecule of the present invention. Neurodegenerative disorders that may be treated and/or prevented by using the binding molecule of the present invention include Alzheimer's disease (AD), Frontotemporal lobar degeneration (FTLD), FTLD-like syndrome, Parkinson's disease, Nasu-Hakola disease, Multiple sclerosis (MS), Huntington disease, immune-mediated neuropathies, or Amyotrophic lateral sclerosis (ALS).

Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

Abstract: The invention concerns pluri- or multipotent stem cells (SCs), e.g. human pluri- or multipotent stem cells (hSCs) engineered to express a multispecific antibody and which further express, on their surface, a human immune cell co-stimulatory ligand or an active fragment thereof.

Abstract: Provided is an isolated TrkB agonist antibody that binds to an epitope contained in one of the extracellular domains of TrkB and is capable of activating TrkB, wherein the extracellular domains comprises extracellular D1, D2, D3, D4, D5 domains and juxtamembrane domain of TrkB. Methods of using the TrkB agonist antibody in treating or reducing the risk of a TrkB associated conditions in a subject, wherein said condition is selected from cell differentiation, synaptic development, neural injury repairing and/or neurite branching.

Abstract: The present invention is directed toward monoclonal antibodies that bind to death receptor 4 and/or death receptor 5, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

Abstract: Herein are provided bispecific anti-human A-beta/human transferrin receptor antibodies and methods of using the same.

Abstract: The disclosure relates to caninized chimeric anti-CD20 antibodies to the canine protein CD20 and methods of use to treat certain disorders such as non-Hodgkins B-cell lymphoma in dogs.

Abstract: The present invention relates to a bispecific binding molecule comprising three binding domains, wherein a first and/or a second binding domain are capable of binding to the extracellular 5T4 antigen and the remaining binding domain(s) is (are) capable of binding to the CD3 receptor complex on T cells. Moreover, the invention relates to a nucleic acid sequence encoding fusion protein, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention relates to a process for the production of the fusion protein of the invention, a medical use of said fusion protein and a kit comprising said fusion protein.

Abstract: Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human MUC16 (monospecific antibodies) and antigen-binding fragments thereof. In some embodiments, the anti-MUC16 antibodies and the antigen-binding fragments thereof are useful in diagnostic methods for identifying the presence of MUC16 in tissue and/or plasma samples.

Abstract: Methods are provided for diagnosing and treating a blood cancer or a myelodysplastic syndrome in a subject. Associated compositions and kits therefor are also provided.

Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.

Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.

Abstract: The invention described herein relates to the discovery that renalase, and fragments thereof, are useful for the treatment or prevention of cardiac and renal diseases or disorders. Thus, the invention relates to compositions comprising renalase, or fragments thereof, and methods for treating and preventing cardiac and renal disease or disorders.

Abstract: The present invention includes an antibody or antigen-binding fragment thereof that binds specifically to TMPRSS2 and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., influenza virus infections).

Abstract: Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.

Abstract: The present invention relates to antibodies that bind blood brain barrier receptors (BBB-R) and methods of using the same.

Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.

Abstract: A method for producing a highly viscous water-soluble cellulose ether has a small undissolved fiber content and a high loose bulk density. More specifically, a production method includes steps of: bringing cellulose pulp into contact with an alkali metal hydroxide solution to obtain an alkali cellulose mixture; draining the alkali cellulose mixture to obtain an alkali cellulose; reacting the alkali cellulose with an etherifying agent to obtain a water-soluble cellulose ether mixture; washing and draining the water-soluble cellulose ether mixture to obtain a first moist cellulose ether; mixing the first moist cellulose ether with water to obtain a second moist cellulose ether; coarsely pulverizing the second moist cellulose ether with a coarse pulverizer to obtain a coarsely pulverized cellulose ether; cooling the coarsely pulverized cellulose ether; and then drying and pulverizing the coarsely pulverized cellulose ether.

Abstract: Provided is a carboxymethyl cellulose or a salt thereof, in which when the carboxymethyl cellulose or the salt thereof is used as a binding agent for an electrode of a nonaqueous electrolyte secondary battery, defects, such as pinholes, on a surface of the electrode are reduced and a battery including the electrode has a good capacity retention. A method for producing a carboxymethyl cellulose or a salt thereof includes an alkali cellulose formation step (step 1) of allowing cellulose and an alkali to react with each other in the presence of a mixed solvent containing water and an organic solvent, an etherification step (step 2) of allowing the resulting alkali cellulose and an etherifying agent to react with each other, a purification step (step 3) of washing and drying the resulting reaction mixture, and a pulverization step (step 4) of pulverizing the resulting purified product.

Abstract: A method for refining sugammadex sodium is provided: adding a protective agent to crude sugammadex sodium, and obtaining pure sugammadex sodium by performing recrystallization under the protection of inert gas. Among them, the protective agent is one or a mixture of two or more, in any ratio, selected from the group consisting of mercaptoethanol, thioglycolate, thioglycolate ester, mercaptopropionate, mercaptopropionate ester, glutathione, cysteine, cystamine, dithioerythritol, dithiothreitol, trisubstituted organophosphorus compound, and salt of the trisubstituted organophosphorus compound. The method is simple in operation, high in product purity, good in economy, and more suitable for industrial production.

Abstract: A high pressure polymerization process to form an ethylene-based polymer, the process comprising at least the following step: polymerizing a reaction mixture comprising ethylene and at least one comonomer, using a reactor system comprising a reactor configuration, and the following: (A) at least two reaction zones, a zone (reaction zone 1) and an ith zone (reaction zone i where i?2), (B) at least two ethylene-based feed streams, each comprising a percentage of the total make-up ethylene fed to the polymerization process, and wherein a first stream is sent to reaction zone 1 and a second stream is sent to reaction zone i; (C) a control system to control the percentage of the total make-up ethylene in the stream sent to reaction zone 1, and the percentage of the total make-up ethylene in the stream sent to reaction zone i, and wherein the ratio (Q) of the molar concentration of the at least one comonomer fed to the first reaction zone, to the molar concentration of comonomer in the sum of all ethylene-based fee

Abstract: A polyolefin production system is provided. The polyolefin production system includes a plurality of gas-phase polymerization tanks configured to polymerize an olefin gas to form a polyolefin, a compressor comprising an inlet and an outlet and being configured to compress a an olefin-containing gas, an individual gas feed line disposed at each of the gas-phase polymerization tanks and configured to guide the gas fed from the outlet of the compressor to each of the gas-phase polymerization tanks, an individual gas discharge line disposed at each of the gas-phase polymerization tanks and discharging the gas from each of the gas-phase polymerization tanks, and a first valve installed in each of the individual gas feed lines.

Abstract: The present invention relates to a process for operating a polymer powder degasser vessel, and in particular provides a process for operating a polymer powder degasser vessel which vessel comprises a silo comprising a main vertical cylinder and a hopper at the bottom of the cylinder, there being a polymer powder withdrawal pipe connected to the hopper by which polymer powder is withdrawn from the hopper, and wherein the silo contains a polymer powder which occupies less than 45% of the volume of the silo and the polymer powder passes through the polymer powder degasser vessel in a mass flow manner, further wherein at least one of the following is applied: i) polymer powder is withdrawn from the hopper and recirculated to the silo, wherein the recirculation rate of the polymer powder is at least 30 percent per hour of the polymer powder present in the silo, and ii) a purge gas is provided to the silo via the polymer powder withdrawal pipe or via an inlet located on the hopper at a vertical height which is less

Abstract: The present invention relates to a multimodal polyethylene composition comprising: (A) 40 to 65 parts by weight, preferably 43 to 52 parts by weight, most preferred 44 to 50 parts by weight, of the low molecular weight polyethylene, the low molecular weight polyethylene having a weight average molecular weight (Mw) of 20,000 to 90,000 g/mol and having a MFRa from 500 to 1.

Abstract: Provided is a composite resin material that yields a resin molded body which has not only a low volume resistivity but also excellent electroconductivity and/or antistatic properties and whose volume resistivity is unlikely to be increased even when subjected to, for example, a washing treatment with ozone water. The composite resin material contains a polychlorotrifluoroethylene and carbon nanotubes and has an average particle diameter of 500 ?m or smaller.

Abstract: This invention relates to photocurable electron deficient olefin-containing compositions, such as those containing certain 2-cyanoacrylates, 2-cyanopentadienoates, methylidene malonates, and vinylidine cyanide, and photolatent bases. When exposed to radiation in the electromagnetic spectrum, the compositions show a delay cure property.

Abstract: This invention relates to processes for forming hydrogen mediated saline hydride initiated anionic polymer distributions via novel polymerization conditions in which molecular hydrogen is a chain transfer agent and a Lithium Aminoalkoxide Complexed Saline Hydride (LOXSH) forms an anionic polymer chain initiating species by addition of saline hydride to an anionically polymerizable hydrocarbon monomer. This invention further relates to polystyrene compositions having greatly improved microstructures free of co-product polymer chain distributions. This invention also relates to novel hydrocarbon soluble saline hydride catalyst and reagent compositions useful in conducting the hydrogen mediated saline hydride initiated polymerizations of this invention. This invention further relates to hydrocarbon soluble lithium hydride catalysts and reagent compositions formed from dimethylaminoethanol, an alkyllithium reagent and molecular hydrogen.

Abstract: The present invention concerns a process for the gas phase polymerization of at least one alpha-olefin comprising: polymerizing at least one alpha-olefin in a fluidized bed reactor with a polyolefin purging unit and a vent gas recovery system, wherein the fluidized bed reactor operates in a condensed mode or super condensed mode with a recycle stream comprising one or more alkane(s) having 3 to 5 C atoms, wherein further at least one additional alkane with 6 to 12 C atoms is added to the recycle stream in an amount so that it represents between 0.0095 mol. % and 7,0000 mol. % of the recycle stream composition introduced into the reactor.

Abstract: This disclosure describes polymerization processes and processes for quenching polymerization reactions using high molecular weight polyhydric quenching agents.